Histone deacetylase inhibitors impair the elimination of hiv-infected cells by cytotoxic t-lymphocytes

PLoS Pathogens

Volumn 10, Issue 8, 2014, Pages

  Jones, Richard Brad ^a   O’Connor, Rachel ^a   Mueller, Stefanie ^a   Foley, Maria ^a,b   Szeto, Gregory L ^a,b   Karel, Dan ^a   Lichterfeld, Mathias ^c   Kovacs, Colin ^d,e   Ostrowski, Mario A ^d,e,f   Trocha, Alicja ^a   Irvine, Darrell J ^a,b,g   Walker, Bruce D ^a,c,g  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d Maple Leaf Medical   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f ST MICHAEL'S HOSPITAL   (Canada)

^g HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALT 803; GAMMA INTERFERON; HISTONE DEACETYLASE INHIBITOR; IONOMYCIN; PANOBINOSTAT; ROMIDEPSIN; SUBERANILOHYDROXAMIC ACID; UNCLASSIFIED DRUG; DEPSIPEPTIDE; HYDROXAMIC ACID; INDOLE DERIVATIVE;

ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ELIMINATION; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CELL VIABILITY; CELL VIABILITY ASSAY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; PERIPHERAL BLOOD MONONUCLEAR CELL; TIME-LAPSE VIDEO MICROSCOPY; VIRAL CLEARANCE; VIREMIA; VIRUS LOAD; CELL SURVIVAL; CYTOTOXICITY; DRUG EFFECTS; IMMUNOLOGY; VIRUS REPLICATION;

CELL PROLIFERATION; CELL SURVIVAL; CYTOTOXICITY, IMMUNOLOGIC; DEPSIPEPTIDES; HISTONE DEACETYLASE INHIBITORS; HIV INFECTIONS; HUMANS; HYDROXAMIC ACIDS; INDOLES; T-LYMPHOCYTES, CYTOTOXIC; VIRUS REPLICATION;

EID: 84912530131     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1004287     Document Type: Article

References (62)

1. Deeks SG (2011) HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 62: 141-155.
2. Deeks SG, Lewin SR, Havlir DV (2013) The end of AIDS: HIV infection as a chronic disease. Lancet 382: 1525-1533.
3. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, et al. (1997) Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A 94: 13193-13197.
4. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, et al. (1997) Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278: 1295-1300.
5. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, et al. (1997) Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278: 1291-1295.
6. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, et al. (1999) Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5: 512-517.
7. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, et al. (2009) HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 15: 893-900.
8. Buzon MJ, Massanella M, Llibre JM, Esteve A, Dahl V, et al. (2010) HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 16: 460-465.
9. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, et al. (2012) Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487: 482-485.
10. Archin NM, Espeseth A, Parker D, Cheema M, Hazuda D, et al. (2009) Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses 25: 207-212.
11. Rasmussen TA, Schmeltz Sogaard O, Brinkmann C, Wightman F, Lewin SR, et al. (2013) Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation. Hum Vaccin Immunother 9: 993-1001.
12. Wightman F, Ellenberg P, Churchill M, Lewin SR (2012) HDAC inhibitors in HIV. Immunol Cell Biol 90: 47-54.
13. Shan L, Deng K, Shroff NS, Durand CM, Rabi SA, et al. (2012) Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36: 491-501.
14. Licciardi PV, Karagiannis TC (2012) Regulation of immune responses by histone deacetylase inhibitors. ISRN Hematol 2012: 690901.
15. Akimova T, Beier UH, Liu Y, Wang L, Hancock WW (2012) Histone/protein deacetylases and T-cell immune responses. Blood 119: 2443-2451.
16. Bosisio D, Vulcano M, Del Prete A, Sironi M, Salvi V, et al. (2008) Blocking TH17-polarizing cytokines by histone deacetylase inhibitors in vitro and in vivo. J Leukoc Biol 84: 1540-1548.
17. Glauben R, Batra A, Fedke I, Zeitz M, Lehr HA, et al. (2006) Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J Immunol 176: 5015-5022.
18. Leoni F, Zaliani A, Bertolini G, Porro G, Pagani P, et al. (2002) The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits anti-inflammatory properties via suppression of cytokines. Proc Natl Acad Sci U S A 99: 2995-3000.
19. Mishra N, Reilly CM, Brown DR, Ruiz P, Gilkeson GS (2003) Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J Clin Invest 111: 539-552.
20. Reddy P, Maeda Y, Hotary K, Liu C, Reznikov LL, et al. (2004) Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graftversus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci U S A 101: 3921-3926.
21. Shi ZJ, Ouyang DY, Zhu JS, Xu LH, He XH (2012) Histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits anti-inflammatory activities through induction of mitochondrial damage and apoptosis in activated lymphocytes. Int Immunopharmacol 12: 580-587.
22. Brogdon JL, Xu Y, Szabo SJ, An S, Buxton F, et al. (2007) Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood 109: 1123-1130.
23. Ge Z, Da Y, Xue Z, Zhang K, Zhuang H, et al. (2013) Vorinostat, a histone deacetylase inhibitor, suppresses dendritic cell function and ameliorates experimental autoimmune encephalomyelitis. Exp Neurol 241: 56-66.
24. Kelly-Sell MJ, Kim YH, Straus S, Benoit B, Harrison C, et al. (2012) The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients. Am J Hematol 87: 354-360.
25. Moreira JM, Scheipers P, Sorensen P (2003) The histone deacetylase inhibitor Trichostatin A modulates CD4+ T cell responses. BMC Cancer 3: 30.
26. Wang B, Morinobu A, Horiuchi M, Liu J, Kumagai S (2008) Butyrate inhibits functional differentiation of human monocyte-derived dendritic cells. Cell Immunol 253: 54-58.
27. Bohmig GA, Krieger PM, Saemann MD, Wenhardt C, Pohanka E, et al. (1997) n-butyrate downregulates the stimulatory function of peripheral blood-derived antigen-presenting cells: a potential mechanism for modulating T-cell responses by short-chain fatty acids. Immunology 92: 234-243.
28. Camelo S, Iglesias AH, Hwang D, Due B, Ryu H, et al. (2005) Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J Neuroimmunol 164: 10-21.
29. Dowdell KC, Pesnicak L, Hoffmann V, Steadman K, Remaley AT, et al. (2009) Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, diminishes lymphoproliferation in the Fas-deficient MRL/lpr(2/2) murine model of autoimmune lymphoproliferative syndrome (ALPS). Exp Hematol 37: 487-494.
30. Garcia BA, Busby SA, Shabanowitz J, Hunt DF, Mishra N (2005) Resetting the epigenetic histone code in the MRL-lpr/lpr mouse model of lupus by histone deacetylase inhibition. J Proteome Res 4: 2032-2042.
31. Larsen L, Tonnesen M, Ronn SG, Storling J, Jorgensen S, et al. (2007) Inhibition of histone deacetylases prevents cytokine-induced toxicity in beta cells. Diabetologia 50: 779-789.
32. Reddy P, Sun Y, Toubai T, Duran-Struuck R, Clouthier SG, et al. (2008) Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J Clin Invest 118: 2562-2573.
33. Wang D, Iclozan C, Liu C, Xia C, Anasetti C, et al. (2012) LBH589 enhances T cell activation in vivo and accelerates graft-versus-host disease in mice. Biol Blood Marrow Transplant 18: 1182-1190 e1181.
34. Bridle BW, Chen L, Lemay CG, Diallo JS, Pol J, et al. (2013) HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy. Mol Ther 21: 887-894.
35. Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, et al. (2008) Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 409: 581-589.
36. Liu T, Kuljaca S, Tee A, Marshall GM (2006) Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat Rev 32: 157-165.
37. Marks PA, Richon VM, Miller T, Kelly WK (2004) Histone deacetylase inhibitors. Adv Cancer Res 91: 137-168.
38. Lindemann RK, Gabrielli B, Johnstone RW (2004) Histone-deacetylase inhibitors for the treatment of cancer. Cell Cycle 3: 779-788.
39. Mayo MW, Denlinger CE, Broad RM, Yeung F, Reilly ET, et al. (2003) Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-kappa B through the Akt pathway. J Biol Chem 278: 18980-18989.
40. Johnstone RW (2002) Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1: 287-299.
41. Tao R, de Zoeten EF, Ozkaynak E, Chen C, Wang L, et al. (2007) Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 13: 1299-1307.
42. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, et al. (1995) Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIVsuppressive factors produced by CD8+ T cells. Science 270: 1811-1815.
43. Beier UH, Akimova T, Liu Y, Wang L, Hancock WW (2011) Histone/protein deacetylases control Foxp3 expression and the heat shock response of Tregulatory cells. Curr Opin Immunol 23: 670-678.
44. Clouse KA, Powell D, Washington I, Poli G, Strebel K, et al. (1989) Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. J Immunol 142: 431-438.
45. Foley MH, Forcier T, McAndrew E, Gonzalez M, Chen H, et al. (2014) High avidity CD8+ T cells efficiently eliminate motile hiv-infected targets and execute a locally focused program of anti-viral function. PLoS One 9: e87873.
46. Rothstein TL, Mage M, Jones G, McHugh LL (1978) Cytotoxic T lymphocyte sequential killing of immobilized allogeneic tumor target cells measured by timelapse microcinematography. J Immunol 121: 1652-1656.
47. Sanderson CJ (1976) The mechanism of T cell mediated cytotoxicity. II. Morphological studies of cell death by time-lapse microcinematography. Proc R Soc Lond B Biol Sci 192: 241-255.
48. Matter A (1979) Microcinematographic and electron microscopic analysis of target cell lysis induced by cytotoxic T lymphocytes. Immunology 36: 179-190.
49. Corporation C (2013) Istodax Package Insert.
50. Zhu X, Marcus WD, Xu W, Lee HI, Han K, et al. (2009) Novel human interleukin-15 agonists. J Immunol 183: 3598-3607.
51. Han KP, Zhu X, Liu B, Jeng E, Kong L, et al. (2011) IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization. Cytokine 56: 804-810.
52. Jennes W, Kestens L, Nixon DF, Shacklett BL (2002) Enhanced ELISPOT detection of antigen-specific T cell responses from cryopreserved specimens with addition of both IL-7 and IL-15-the Amplispot assay. J Immunol Methods 270: 99-108.
53. Strengell M, Matikainen S, Siren J, Lehtonen A, Foster D, et al. (2003) IL-21 in synergy with IL-15 or IL-18 enhances IFN-gamma production in human NK and T cells. J Immunol 170: 5464-5469.
54. Shapiro GI, Frank R, Dandamudi UB, Hengelage T, Zhao L, et al. (2012) The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer. Cancer Chemother Pharmacol 69: 555-562.
55. Wei DG, Chiang V, Fyne E, Balakrishnan M, Barnes T, et al. (2014) Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing. PLoS Pathog 10: e1004071.
56. Rubin EH, Agrawal NG, Friedman EJ, Scott P, Mazina KE, et al. (2006) A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer. Clin Cancer Res 12: 7039-7045.
57. Mejia EJ, Loveridge ST, Stepan G, Tsai A, Jones GS, et al. (2014) Study of Marine Natural Products Including Resorcyclic Acid Lactones from Humicola fuscoatra That Reactivate Latent HIV-1 Expression in an in Vitro Model of Central Memory CD4+ T Cells. J Nat Prod 77: 618-24.
58. Jones RB, Yue FY, Gu XX, Hunter DV, Mujib S, et al. (2009) Human immunodeficiency virus type 1 escapes from interleukin-2-producing CD4+ Tcell responses without high-frequency fixation of mutations. J Virol 83: 8722-8732.
59. Streeck H, Frahm N, Walker BD (2009) The role of IFN-gamma Elispot assay in HIV vaccine research. Nat Protoc 4: 461-469.
60. Walker BD, Flexner C, Birch-Limberger K, Fisher L, Paradis TJ, et al. (1989) Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 86: 9514-9518.
61. Jones RB, Garrison KE, Mujib S, Mihajlovic V, Aidarus N, et al. (2012) HERVK-specific T cells eliminate diverse HIV-1/2 and SIV primary isolates. J Clin Invest 122: 4473-4489.
62. Sacha JB, Watkins DI (2010) Synchronous infection of SIV and HIV in vitro for virology, immunology and vaccine-related studies. Nat Protoc 5: 239-246.